Possibilities for the use of anakinra in COVID-19
Open Access
- 28 October 2020
- journal article
- Published by Publishing House OKI in Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice
- No. 4S,p. 60-63
- https://doi.org/10.37489/2588-0519-2020-s4-60-63
Abstract
The use of anakinra cannot be currently recommended outside of clinical trials as pathogenetic treatment of “cytokine storm” in severe COVID-19.Keywords
This publication has 5 references indexed in Scilit:
- Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe COVID-19: A case reportInternational Journal of Infectious Diseases, 2020
- Use of anakinra in severe COVID-19: A case reportInternational Journal of Infectious Diseases, 2020
- Correlation Analysis Between Disease Severity and Inflammation-related Parameters in Patients with COVID-19 PneumoniaPublished by Cold Spring Harbor Laboratory ,2020
- Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathologySeminars in Immunopathology, 2017
- Plasma inflammatory cytokines and chemokines in severe acute respiratory syndromeClinical and Experimental Immunology, 2004